ANNA KEMNER: Open Payments
NPI 1871192781 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$496 in 22 payments from 10 companies in 2025. Trend: 2023 $2,097 · 2024 $1,036 · 2025 $496
Food & beverage: $496
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $299 |
| Janssen Biotech, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| QOL Medical, LLC | 1 | $20 |
| PFIZER INC. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Celltrion USA Inc. | 1 | $15 |
Products named: MAVYRET, RINVOQ, SKYRIZI, TREMFYA, LINZESS, DUPIXENT, XIFAXAN, ENTYVIO.
Industry payments across MO — which companies pay providers there.
